Ungerechts, Guy*

Seminar Title: 

KEYNOTE 3 - The era of cell and gene therapies in oncology - Fiction, poetry, or science? (26th Congress - Hospital pharmacists – changing roles in a changing world)

Affiliation: 

National Center for Tumor Diseases (NCT) Heidelberg, Medical Oncology Department - Deputy Director

Country: 

Germany

1. Current Status, Position

Guy Ungerechts MD, PhD is Deputy Director of the Medical Oncology Department at the National Center for Tumor Diseases (NCT) Heidelberg, and heads the Clinical Cooperation Unit Virotherapy at DKFZ.

2. Education

Guy Ungerechts MD, PhD is a medical oncologist trained in the field of oncolytic viruses at Mayo Clinic, Rochester, USA and at the Ottawa Hospital Research Institute (OHRI), Ottawa, Canada. His clinical focus is GI oncology with particular interests in translational medicine and early clinical trials of immuno(viro)therapy.

3. Research Area

Guy has been responsible for the development and conduction of several Phase I/II and III trials with oncolytic viruses derived from different platforms including oncolytic measles virus, vaccinia virus (JX-594), parvovirus H-1 and herpes simplex virus (HSV-1). His group recently demonstrated for the first time that measles virus can be armed with immunomodulatory transgenes encoding for cytokines, immune checkpoint blockade antibodies and bispecific T cell engager (BITEs) for enhanced immunovirotherapy. Between 2015 and 2020 he was holding an Ontario Institute for Cancer Research (OICR) sponsored clinician-scientist position in Ottawa, Canada. As a staff medical oncologist, he was member of the GI cancer group at The Ottawa Hospital (TOH) between 2015 and 2017. He is adjunct professor at the University of Ottawa and affiliated investigator at the OHRI in Dr. John Bell´s research program.

4. Conflict of interest

None